and number three is that we increase the clerps of the preon form that we get rid of it. and we get to a point when the level of the preon form is low enough. we don't have to get it to zero but we need to get if down fairly far in some people, and then at that point, the normal clearance mechanisms take over in the brain. we can think about this in a very different way than we did initially one is i think the therapies can work for a few weeks or a few months. they can be short term. they don't need to be years, and if we have to go back and re-treat somebody, that's fine. so you spoke about-- anne spoke about the diagnosis of huntington's disease and having a genetic test for this. i think in all these disease we're going to need very good imaging techniques, and we saw this with stanley's demonstration of what goes on in the parkinson's disease in the flora dopa scan. we need to be able to follow these proteins. we have to look at the precursor form. we have to look at the preons when they're small aggregates and then look at the large aggregates, the fibers. so this i